

Drugs with increased applicable percentage

HCPCS	HCPCS Descriptor	Approval Date	Brand Name	Unique Circumstances	Applicable Percentage
J2778	Injection, ranibizumab, 0.1 mg	06/30/2006	Lucentis	Low volume dose 0.05 ml	90%
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	11/29/2007	Triesence	Low volume dose 0.025 – 0.1 ml	90%
J0775	Injection, collagenase, clostridium histolyticum, 0.01 mg	02/02/2010	Xiaflex	Low volume dose 0.2 – 0.39 ml	45%
J0178	Injection, aflibercept, 1 mg	11/18/2011	Eylea	Low volume dose 0.05 ml	90%
J7315	Mitomycin, ophthalmic, 0.2 mg	02/08/2012	Mitosol	Low volume dose 0.1 – 0.2 ml	45%
J7316	Injection, ocriplasmin, 0.125 mg	10/17/2012	Jetrea	Low volume dose 0.1 ml	90%
J3398	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes	12/19/2017	Luxturna	Low volume dose 0.3 ml	45%
J1095	Injection, dexamethasone 9 percent, intraocular, 1 microgram	02/09/2018	Dexycu	Low volume dose 0.005 ml	90%
J0179	Injection, brolocizumab-dbl, 1 mg	10/07/2019	Beovu	Low volume dose 0.05 ml	90%
J9281	Mitomycin pyelocalyceal instillation, 1 mg	05/01/2020	Jelmyto	Pyelocalyceal	35%
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	09/17/2021	Byooviz Nuna	Low volume dose 0.05 ml	90%
J3299	Injection, triamcinolone acetonide (xipere), 1 mg	10/22/2021	Xipere	Low volume dose 0.1 ml	90%
J2779	Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg	10/22/2021	Susvimo	Low volume dose 0.02 ml	Excluded from definition of refundable drug (filtered)

J9274	Injection, tebentafusp-tebn, 1 microgram	01/25/2022	Kimmtrak	Low volume dose 0.1 – 0.34 ml	45%
J2777	Injection, faricimab-svoa, 0.1 mg	01/28/2022	Vabysmo	Low volume dose 0.05 ml	90%
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	08/02/2022	Cimerli	Low volume dose 0.05 ml	90%
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	02/17/2023	Syfovre	Low volume dose 0.1 ml	90%
J3490	Unclassified drug	09/25/2023	Ryzumvi	Low volume dose 0.31 ml	45%